サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ペニシリン・ストレプトマイシンの世界市場（2022年～2028年）
市場調査レポート
商品コード
1078040

ペニシリン・ストレプトマイシンの世界市場（2022年～2028年）

Global Penicillin and Streptomycin Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 130 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ペニシリン・ストレプトマイシンの世界市場（2022年～2028年）
出版日: 2022年04月13日
発行: Orion Market Research
ページ情報: 英文 130 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のペニシリン・ストレプトマイシンの市場規模は、予測期間中にCAGRで2.1％の成長が予測されています。衛生不良による細菌感染が、耳や副鼻腔の感染症、歯の感染症、皮膚の感染症、膀胱や腎臓の感染症、その他の慢性疾患などで急増しており、市場の成長を促進すると予想されています。

当レポートでは、世界のペニシリン・ストレプトマイシン市場について調査分析し、市場概要、競合情勢、セグメント分析、地域分析などを提供しています。

目次

第1章 レポートサマリー

第2章 市場概要と考察

  • 調査範囲
  • アナリストの考察と現在の市場動向

第3章 競合情勢

  • 主要企業分析
    • Abbott Laboratories, Inc.
    • Alembic Pharmaceuticals, Ltd.
    • Astellas Pharma, Inc.
    • Bayer AG
    • Biogen International GmbH
  • 主要戦略分析
  • 主要企業に対するCOVID-19の影響

第4章 市場セグメンテーション

  • 世界のペニシリン・ストレプトマイシン市場：製品別
    • ペニシリン
    • ストレプトマイシン
  • 世界のペニシリン・ストレプトマイシン市場：製造プロセス別
    • ペニシリン
    • ストレプトマイシン
  • 世界のペニシリン・ストレプトマイシン市場：投与経路別
    • 経口
    • 筋肉注射
    • 静脈注射
  • 世界のペニシリン・ストレプトマイシン市場：エンドユーザー別
    • 病院
    • 診療所
    • その他（臨床検査室）

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他の欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋
  • その他の地域

第6章 企業プロファイル

  • Alembic Pharmaceuticals, Ltd.
  • Astellas Pharma, Inc.
  • Bayer AG
  • Biogen International GmbH
  • Bristol-Myers Squibb Co.
  • Eli Lilly & Co.
  • F. Hoffmann La Roche, Ltd.
  • GlaxoSmithKline PLC
  • Jiangxi Dongfeng Pharmaceutical Co., Ltd.
  • Lonza AG
  • Merck & Co., Inc.
  • MODASA Pharmaceuticals Pvt. Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Abbott Laboratories, Inc.
  • Corden Pharma GmbH
図表

LIST OF TABLES

  • 1. GLOBALPENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
  • 2. GLOBAL PENICILLIN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY MANUFACTURING PROCESS, 2021-2028 ($ MILLION)
  • 5. GLOBAL PENICILLIN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
  • 8. GLOBAL ORAL PENICILLIN AND STREPTOMYCIN SYSTEM MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL INTRAMUSCULAR PENICILLIN AND STREPTOMYCIN SYSTEM MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL INTRAVENOUS PENICILLIN AND STREPTOMYCIN SYSTEM MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 11. GLOBAL PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 12. GLOBAL PENICILLIN AND STREPTOMYCIN IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 13. GLOBAL PENICILLIN AND STREPTOMYCIN IN CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 14. GLOBAL PENICILLIN AND STREPTOMYCIN IN OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 15. GLOBAL PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 16. NORTH AMERICAN PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 17. NORTH AMERICAN PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
  • 18. NORTH AMERICAN PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY MANUFACTURING PROCESS, 2021-2028 ($ MILLION)
  • 19. NORTH AMERICAN PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
  • 20. NORTH AMERICAN PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 21. EUROPEAN PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 22. EUROPEAN PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
  • 23. EUROPEAN PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY MANUFACTURING PROCESS, 2021-2028 ($ MILLION)
  • 24. EUROPEAN PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
  • 25. EUROPEAN PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 26. ASIA-PACIFIC PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 27. ASIA-PACIFIC PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
  • 28. ASIA-PACIFIC PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY MANUFACTURING PROCESS, 2021-2028 ($ MILLION)
  • 29. ASIA-PACIFIC PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
  • 30. ASIA-PACIFIC PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY END-USER 2021-2028 ($ MILLION)
  • 31. REST OF THE WORLD PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
  • 32. REST OF THE WORLD PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY MANUFACTURING PROCESS, 2021-2028 ($ MILLION)
  • 33. REST OF THE WORLD PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
  • 34. REST OF THE WORLD PENICILLIN AND STREPTOMYCIN MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBALPENICILLIN AND STREPTOMYCINMARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBALPENICILLIN AND STREPTOMYCINMARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBALPENICILLIN AND STREPTOMYCINMARKET, 2021-2028 (%)
  • 4. GLOBAL PENICILLIN AND STREPTOMYCIN MARKET SHARE BY PRODUCT, 2021 VS 2028 (%)
  • 5. GLOBAL PENICILLIN AND STREPTOMYCIN MARKET SHARE BY MANUFACTURING PROCESS, 2021 VS 2028 (%)
  • 6. GLOBAL PENICILLIN AND STREPTOMYCIN MARKET SHARE BY ROUTE OF ADMINISTRATION, 2021 VS 2028 (%)
  • 7. GLOBAL PENICILLIN AND STREPTOMYCIN MARKET SHARE BY END-USER, 2021 VS 2028 (%)
  • 8. GLOBAL PENICILLIN AND STREPTOMYCIN MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. US PENICILLIN AND STREPTOMYCIN SIZE, 2021-2028 ($ MILLION)
  • 10. CANADA PENICILLIN AND STREPTOMYCIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 11. UK PENICILLIN AND STREPTOMYCIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 12. FRANCE PENICILLIN AND STREPTOMYCIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 13. GERMANY PENICILLIN AND STREPTOMYCIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 14. ITALY PENICILLIN AND STREPTOMYCIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 15. SPAIN PENICILLIN AND STREPTOMYCIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. ROE PENICILLIN AND STREPTOMYCIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. INDIA PENICILLIN AND STREPTOMYCIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. CHINA PENICILLIN AND STREPTOMYCIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. JAPAN PENICILLIN AND STREPTOMYCIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. REST OF ASIA-PACIFIC PENICILLIN AND STREPTOMYCIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. REST OF THE WORLD PENICILLIN AND STREPTOMYCIN MARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: PH1311

Global Penicillin and Streptomycin Market Size, Share & Trends Analysis Report By Product (Penicillin, Streptomycin) By Manufacturing Process (Penicillin, Streptomycin,) By Route of Administration (Oral, Intramuscular, Intravenous) By End-User (Hospitals, Clinics and Others-Clinical Laboratories) Forecast 2022-2028

The global Penicillin and Streptomycinmarket is anticipated to grow at a substantial CAGR of 2.1% during the forecast period.Owing to the poor sanitation the bacterial infection is rising in the number of diseases such as ear and sinus infections, Dental infections, Skin infections,Bladder and kidney infections,and other chronic diseases, which is expected to drive the growth of the global Penicillin and Streptomycin market. According to WHO, Over 1.7 billion people still do not have basic sanitation services, such as private toilets or latrines. Out of these 494 million still defecate in the open, for example in street gutters, behind bushes or into open bodies of water.Some 829 000 people in low- and middle-income countries die as a result of inadequate water, sanitation, and hygiene each year, representing 60% of total diarrhoeal deaths.

The global Penicillin and Streptomycin market is segmented based on products, Manufacturing Process, Route of Administration, and end-user. Based on products the market is sub-divided into Penicillin, Streptomycin. Based on the manufacturing process the market is bifurcated into penicillin and Streptomycin which is further subdivided into Natural Process, Synthetic Process and Semi-Synthetic Process. Based on Route of Administration the market is sub-segmented into Oral, Intramuscular and Intravenous. Based on end-user, the market is sub-segmented into hospitals, Clinics, Others (Clinical Laboratories) .The hospital segment is anticipated to grow at the fastest rate, as hospitals assist the patients to take medical help from doctors who in return tell to take these antibiotics.The increasing number of bacterial infected patients along with growing awareness regarding the various benefits and facilities provided in hospitals is considered a prime factor that is supporting the growth of the hospital segment. According to PLOS ONE journal, the three most commonly prescribed antibiotics in the world are penicillins, third-generation cephalosporins, and fluoroquinolones.

Geographically market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America dominates the market and is expected to continue its presence over the forecast period. The growth can be attributed to the increasing adoption of Penicillin and Streptomycinantibiotics in infection treatment.Also the increasing R&D in the field of antibiotics with new product development is also fuelling the market. For Instance, in 2019 The US Food and Drug Administration, approved new antibiotic to treat community-acquired bacterial pneumoniawhich has contributed to the growth of the market in the North America region.

The major companies serving the global Penicillin and Streptomycinmarket are Thermofisher Scientific, Inc. , Takeda Pharmaceutical Co., Ltd. , Sanofi-Aventis Group , Pfizer, Inc. , Novartis AG and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in 2021 Pfizer acquired Arena Pharmaceuticals. The Proposed acquisition offers a potentially new, differentiated best-in-class approach to address unmet need for a broader number of patients with immuno-inflammatory diseases.

Research Methodology

The market study of the global Penicillin and Streptomycinmarket is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, researchpapers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Penicillin and StreptomycinMarket Research and Analysis by Product

2. Global Penicillin and StreptomycinMarket Research and Analysis by Manufacturing Process

3. Global Penicillin and StreptomycinMarket Research and Analysis by Route of Administration

4. Global Penicillin and StreptomycinMarket Research and Analysis by End-User

The Report Covers

  • Comprehensive research methodology of the globalPenicillin and Streptomycinmarket.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global Penicillin and Streptomycinmarket.
  • Insights about market determinants that are stimulating the global Penicillin and Streptomycinmarket.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

Category-Pharmaceuticals

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the GlobalPenicillin and StreptomycinMarket
  • Recovery Scenario of GlobalPenicillin and StreptomycinMarket
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key CompanyAnalysis
    • 3.1.1. Abbott Laboratories, Inc.
      • 3.1.1.1. Overview
      • 3.1.1.2. Financial Analysis
      • 3.1.1.3. SWOT Analysis
      • 3.1.1.4. Recent Developments
    • 3.1.2. Alembic Pharmaceuticals, Ltd.
      • 3.1.2.1. Overview
      • 3.1.2.2. Financial Analysis
      • 3.1.2.3. SWOT Analysis
      • 3.1.2.4. Recent Developments
    • 3.1.3. Astellas Pharma, Inc.
      • 3.1.3.1. Overview
      • 3.1.3.2. Financial Analysis
      • 3.1.3.3. SWOT Analysis
      • 3.1.3.4. Recent Developments
    • 3.1.4. Bayer AG
      • 3.1.4.1. Overview
      • 3.1.4.2. Financial Analysis
      • 3.1.4.3. SWOT Analysis
      • 3.1.4.4. Recent Developments
    • 3.1.5. Biogen International GmbH
      • 3.1.5.1. Overview
      • 3.1.5.2. Financial Analysis
      • 3.1.5.3. SWOT Analysis
      • 3.1.5.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of Covid-19 on Key Players

4. Market Segmentation

  • 4.1. GlobalPenicillin and StreptomycinMarket, by Product
    • 4.1.1. Penicillin
    • 4.1.2. Streptomycin
  • 4.2. Global Penicillin and StreptomycinMarket, byManufacturing Process
    • 4.2.1. Penicillin
      • 4.2.1.1. Natural Process
      • 4.2.1.2. Synthetic Process
      • 4.2.1.3. Semi-Synthetic Process
    • 4.2.2. Streptomycin
      • 4.2.2.1. Natural Process
      • 4.2.2.2. Synthetic Process
      • 4.2.2.3. Semi-Synthetic Process
  • 4.3. Global Penicillin and Streptomycin Market, by Route of Administration
    • 4.3.1. Oral
    • 4.3.2. Intramuscular
    • 4.3.3. Intravenous
  • 4.4. Global Penicillin and Streptomycin Market, by End-user
    • 4.4.1. Hospitals
    • 4.4.2. Clinics
    • 4.4.3. Others (Clinical Laboratories)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Alembic Pharmaceuticals, Ltd.
  • 6.2. Astellas Pharma, Inc.
  • 6.3. Bayer AG
  • 6.4. Biogen International GmbH
  • 6.5. Bristol-Myers Squibb Co.
  • 6.6. Eli Lilly & Co.
  • 6.7. F. Hoffmann La Roche, Ltd.
  • 6.8. GlaxoSmithKline PLC
  • 6.9. Jiangxi Dongfeng Pharmaceutical Co., Ltd.
  • 6.10. Lonza AG
  • 6.11. Merck & Co., Inc.
  • 6.12. MODASA Pharmaceuticals Pvt. Ltd.
  • 6.13. Novartis AG
  • 6.14. 7.16. Pfizer, Inc.
  • 6.15. Abbott Laboratories, Inc.
  • 6.16. Corden Pharma GmbH